Lilly shares trade down after fourth-quarter profits falls
Analysts worry about dive in already paltry sales of new blood thinner Effient
Eli Lilly and Co.
Articles
Lilly’s profits fall, miss analyst expectations
The Indianapolis-based drugmaker says a weaker dollar depressed earnings in the fourth quarter compared with a year ago.
Lilly looks to autoimmune drugs
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.
Lilly shares get boost from OK of rival’s drug
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.
Biotech firm plans $28M Greenwood plant
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
FDA letters scold Lilly, others over marketing materials
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately
display information about the drug’s side effects.
FDA cancels meeting to review Lilly’s Cymbalta
The agency said the meeting was canceled “to allow time for the FDA to review new information” about a proposed new use for
the drug.
Ruth Lilly remembered for ‘selfless’ giving
Lilly, 94, who died Wednesday, gave away hundreds of millions of dollars of her fortune during her lifetime.
Eli Lilly and Co. heiress Ruth Lilly dies at 94
Over the course of her life, the last surviving great-grandchild of pharmaceutical magnate Eli Lilly gave away much of her
inheritance.
Corporations bet on insiders to bend reform
Indianapolis health care heavyweights are among those spending $635 million, employing 166 former aides to key congressional
leaders and committees in health reform process.
To keep sales force busy, Lilly takes on new drug
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel
to push.
Lilly scurries to get out from under Zyprexa cloud
Another year of rapid change at Eli Lilly and Co. did little to move the company out from under the cloud cast by its best-selling
drug, Zyprexa.
Lilly pays $90 million for autoimmune drug
By acquiring an experimental medicine for rheumatoid arthritis, the Indianapolis-based drugmaker is increasing its focus on autoimmune
diseases.
Senate rejects drug-importation proposal
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
Lilly wins approval for long-acting Zyprexa
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Lilly charity gives $1M to new IU health school
The Eli Lilly and Co. Foundation has given Indiana University $1 million to start a school of public health at Indiana University-Purdue
University Indianapolis.
Eli Lilly’s shares slip after it forecasts mixed profits in coming years
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
Lilly launching new venture capital fund
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
Lilly forecasts growth in earnings next year
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
Ariad asks court to restore patent-suit win against Lilly
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.